Although two heavy hitters' drugs have been approved in the marginal zone lymphoma (MZL) setting where New York-based TG Therapeutics Inc. is due to report important data during the fourth quarter, the company just might have an edge with its oral PI3K-delta inhibitor, umbralisib.